https://www.live-feeds.com/feed/eli-lilly-s-diabetes-drug-mounjaro-gets-approval-for-a-new-useContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/eli-lilly-s-diabetes-drug-mounjaro-gets-approval-for-a-new-usehttps://www.live-feeds.com/feed/eli-lilly-s-diabetes-drug-mounjaro-gets-approval-for-a-new-use#u54530Wed, 02 Sep 2026 07:30:34 +0000The FDA approved Eli Lilly's tirzepatide, marketed as Mounjaro, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for such events. This new indication allows the GLP-1 medication to be used specifically to reduce risks including strokes. The approval expands the drug's utility beyond glucose management to include the prevention of heart disease and related cardiovascular complications in this patient population.Why it mattersMounjaro belongs to a class of GLP-1 receptor agonists used for diabetes and weight management. Reduci https://www.live-feeds.com/feed/eli-lilly-s-diabetes-drug-mounjaro-gets-approval-for-a-new-usehttps://www.live-feeds.com/feed/eli-lilly-s-diabetes-drug-mounjaro-gets-approval-for-a-new-use#u52893Mon, 31 Aug 2026 08:15:27 +0000The US Food and Drug Administration approved Eli Lilly's diabetes medication Mounjaro, known as tirzepatide, for a new indication to reduce cardiovascular risk. This approval specifically targets adults living with type 2 diabetes. The drug is now authorized to lower the risk of heart disease and related heart events in this patient population.Why it mattersMounjaro was previously used primarily for blood sugar management in diabetes patients. Expanding the drug's approved use to include heart health increases its clinical utility for high-risk patients. This move follows a trend of